The intracranial response rate reached 41%, with 3 cases of intracranial lesions achieving complete remission! The clinical results of ESG401 for brain metastasis from Escugen Biotechnology have been published in an internationally renowned journal
On May 13, 2025, the clinical research results of ESG401, a TROP2 ADC drug developed by Escugen Biotechnology for treating brain metastasis in patients with advanced HER2-negative breast cancer, were officially published online in ESMO Open, a well-known international medical journal hosted by the European Society for Medical Oncology (ESMO). The paper is titled "Novel TROP2 antibody–drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option." The article reports the efficacy and safety data of ESG401 in HER2-negative breast cancer patients with brain metastasis.
2025-05-14
